Iain was appointed to the Board in November 2007 and is currently serving as Chairman.
Iain is an experienced private consultant, investor and nonexecutive director (both listed and unlisted public companies). He has considerable practical and operational experience gained from a successful financial career spanning 35 years in a range of industries including auditing, resources, manufacturing and latterly healthcare in Australia, Britain and the USA. He started his career at Arthur Andersen & Co in London. Before establishing himself as a consultant/advisor and joining a number of boards as a non‑executive director, Iain held a range of senior financial and general management positions in Woodside Petroleum Ltd, Santos Ltd, Pilkington plc, F.H. Faulding & Co Ltd and Clinuvel Pharmaceuticals Limited.
Iain is a Non‑Executive Director of ASX listed companies Medical Developments International Ltd (ASX:MVP), Vision Group Holdings Ltd (ASX:VGH) and Chairman of Avexa Limited (ASX:AVX).
Andrew brings to Bluechiip vast experience in innovation and commercialisation combined with significant technical and operational experience. Prior to joining Bluechiip, as CEO of the Advanced Manufacturing Co‑operative Research Center (AMCRC), Andrew focused on bringing together industry and research to develop and commercialize ground breaking innovations. He has held a range of senior positions including Director at Leica Microsystems (previously Vision BioSystems a division of the publicly listed Vision Systems), Vice President of Marketing and Business Development North America and Director of Product Management at Vision BioSystems Pty Ltd.
Andrew is a non‑executive Director at AMCRC and holds a Bachelor of Engineering Degree (Hons) and an MBA (Strategy) from Monash University. In addition, he is also a graduate of the Australian Institute of Company Directors (GAICD).
Lee was previously a partner in a premier mid‑tier law firm in their corporate group. He remains a qualified solicitor practising principally in corporate and commercial law advising on corporate and securities regulation, capital raisings, formulation and implementation of mergers and acquisitions, corporate governance and secretarial matters.
Mr. Ohanessian is the CEO and Managing Director of Praemium Ltd, a provider of portfolio administration and SMA technology to financial services providers in Australia and around the globe. Mr Ohanessian’s executive experience in technology‑related businesses brings a mixture of operational, strategic and leadership capabilities to his role at Bluechiip. Following a ten‑year career at Mobil Oil, Mr. Ohanessian joined the Boston Consulting Group where he consulted to clients in a wide range of industries including banking, aviation, mining, packaging, sports, oil and gas, retailing and importantly, biotechnology.
During his seven years as CEO of Vision BioSystems, a division of the publicly‑listed Vision Systems, he transformed the business from a small, unprofitable contract manufacturer into a vertically integrated, profitable and growing medical diagnostics business with distribution to over 60 countries. More recently he served as the CEO of Genetic Technologies and was involved in investment management and corporate advice with Lion Capital prior to joining Praemium Ltd